April 28, 2022

SAN RAMON, CALIF., April 28, 2022— CooperVision, one of the world’s foremost authorities on myopia management, will share new data and analysis demonstrating the performance and efficacy of its innovative MiSight® 1 day contact lens during next week’s 2022 Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver.

“The increasing severity and prevalence of myopia progression in children is one of the greatest healthcare issues today, with consequences that will last for generations,” said Paul Chamberlain, BSc (Hons), Director of Research Programs for CooperVision. “Our extensive scientific and commercial innovations have made it easier for eye care professionals to address this challenge and incorporate myopia management as the standard of care. The works we are presenting at ARVO build further confidence in MiSight® 1 day contact lenses* as a preferred approach.”  

Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing (Meyer D, et al) presents evidence that myopia control using MiSight® 1 day contact lenses is achieved through added myopic defocus, validating prior hypotheses.1 The study also quantified the myopic defocus dose delivered to children in two ways: by diopters and by the proportion of light focused in front of the retina. This work was conducted with the Indiana University School of Optometry.

Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear (Hammond D, et al) offers further in-depth analysis of the seven-year MiSight® 1 day clinical trial, which is the longest-running soft contact lens study among children. CooperVision previously reported that twelve months following treatment cessation, mean axial elongation data indicated no evidence of rebound effect, signifying the myopia control gains were retained among the entire cohort. 2,3

This latest work provides a deeper dive into the year seven data. These results indicate that treatment effects are retained regardless of when treatment ceased at any age between 14 to 18. The investigators conclude that starting MiSight® 1 day at a younger age and continuing throughout teenage years reduces time during which untreated eye growth can occur.4

CooperVision’s additional ARVO 2022 research presentations, including advancements in contact lens comfort science and other topics, can be viewed at arvo.org/annual-meeting/

# # #

Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval of MiSight® 1 day.

Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.

* U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.


About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Mike McDougall, APR, Fellow PRSA, McDougall Communications
mike@mcdougallpr.com or +1-585-434-2150


1 Meyer D, et al. Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing. ARVO 2022 poster presentation.

2 Chamberlain P, Arumugam B, et al. Myopia Progression on Cessation of Dual-Focus Contact Lens Wear: MiSight 1 day 7-Year Findings. Optom Vis Sci 2021;98:E-abstract 210049

3 Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with No Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130

4 Hammond D, et al. Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear. ARVO 2022 poster presentation.